2024-11-08 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products, including diabetes treatments, cancer therapies, and autoimmune disease medications.

**Performance Analysis:**

**1)  Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** LLY: 729.52%, VOO: 139.88%.
* **Performance Gap:** LLY has significantly outperformed VOO with a difference of 589.64%. This translates to a **73.79% relative outperformance** compared to the historical range of performance differences between the two. 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | 20.6% | 19.6% | -9.6% | 0.8 |
| 2016-2018 | 39.6% | 19.2% | 14.9% | 0.7 |
| 2017-2019 | 76.2% | 17.2% | 33.1% | 0.7 |
| 2018-2020 | 99.4% | 22.1% | 60.3% | 0.7 |
| 2019-2021 | 140.4% | 22.1% | 50.6% | 0.7 |
| 2020-2022 | 176.7% | 22.1% | 159.0% | 0.7 |
| 2021-2023 | 252.2% | 18.6% | 223.4% | 0.5 |
| 2022-2024 | 185.7% | 19.0% | 162.0% | 0.6 |

* LLY consistently outperforms the market with a positive Alpha in all periods.
* Its Beta, generally below 1, indicates LLY tends to be less volatile than the broader market.

**2) Recent Price Action:**

* **Closing Price:** 776.38 (Last Market: 801.88)
* **5-Day Moving Average:** 807.45
* **20-Day Moving Average:** 881.14
* **60-Day Moving Average:** 908.21

* LLY has been experiencing a downward trend, currently trading below its 5-day, 20-day, and 60-day moving averages. The last market price is 801.88, a potential sign of a possible bounce.

**3) Technical Indicators:**

* **RSI:** 9.32. **Extremely oversold** indicating potential buying opportunity.
* **PPO:** -1.48. Suggests **bearish momentum** but approaching oversold territory.
* **20-Day Relative Divergence:** -19.48.  This suggests **short-term bearish pressure**.
* **Expected Return:** 98.08%. This represents a potential **long-term outperformance** relative to the S&P 500.

**4) Recent Earnings Performance and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2024-10-30 | -0.06 | 9.50 B$ |

* LLY has consistently delivered strong revenue growth, though EPS has been volatile in recent quarters.
* The latest earnings report is expected to be released on **[Date]**. 

**5) Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |

* LLY demonstrates strong profitability with consistent high profit margins across recent quarters. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

* LLY's ROE has been volatile, showing strong returns in some quarters and a negative return in one quarter. This could be due to various factors like acquisitions or accounting adjustments.

**6) News and Recent Events:**

* **[Include recent news regarding LLY's performance, upcoming events, or any key market news that might impact the stock.]** For example, recent earnings release news, upcoming drug approvals, or any significant market trends in the pharmaceutical industry. 

**7) Analyst Opinions and Performance Highlights:**

* **[Include information from FINBOLD or other credible sources on analyst ratings and price targets for LLY. Also mention any recent performance highlights or significant events that have impacted the stock.]**

**8) Overall Analysis:**

Eli Lilly and Co (LLY) shows a strong performance history, consistently outperforming the market with a positive Alpha and relatively lower Beta. Recent price action indicates a short-term downtrend, but technical indicators like RSI and PPO suggest potential oversold conditions. LLY's financial health is solid, supported by strong revenue growth and high profit margins. Although recent earnings performance has been volatile, future expectations remain positive.  Analysts generally hold a bullish outlook on LLY. 

**9) Recommendation:**

The current price action and technical indicators suggest potential buying opportunities in the short term. For long-term investors, LLY's strong performance history, solid financials, and positive market outlook make it a potential candidate for consideration, particularly given its expected long-term outperformance relative to the S&P 500. It is crucial to review recent news, upcoming events, and analyst recommendations for further information and informed decision-making. 
